Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Frequent loss of FUS1 protein expression is associated with lung cancer development.
|
21273575 |
2011 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inhibitory Fus1 sequence was derived from a region that was deleted in a mutant FUS1 gene (FUS1 (1-80)) detected in some lung cancer cell lines.
|
17486070 |
2007 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results demonstrated an important role of FUS1 in modulating chemosensitivity of lung cancer cells, and suggested that a proper combination of molecular therapeutics such as the proapoptotic tumor suppressor FUS1 and the conventional chemotherapeutic drugs such as cisplatin may be an efficient treatment strategy for human lung cancer.
|
17828283 |
2008 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Restoration of FUS1 function in human non-small cell lung cancer (NSCLC) cells was found to significantly inhibit tumor cell growth and modulate the chemosensitivity of lung cancer cells.
|
26081814 |
2015 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This ability to modify the tumor microenvironment suggests that TUSC2 could be added to checkpoint inhibitors to improve the treatment of lung cancer.
|
29296193 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We defined coexpression of LKB1 and FUS1 could synergistically inhibited lung cancer cells growth,invasion and migration and induced the cell apoptosis and arrested cell cycle in vitro.
|
24659339 |
2014 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also found that a systemic treatment with a combination of FUS1 and p53 nanoparticles synergistically suppressed the development and growth of tumors in a human H322 lung cancer orthotopic mouse model.
|
17234782 |
2007 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results show that myristoylation is required for Fus1-mediated tumor-suppressing activity and suggest a novel mechanism for the inactivation of tumor suppressors in lung cancer and a role for deficient posttranslational modification in tumor suppressor-gene-mediated carcinogenesis.
|
15126327 |
2004 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings show a high frequency of Fus1 protein loss and reduction of expression in lung cancer, and suggests that this reduction may play an important role in the early pathogenesis of lung squamous cell carcinoma.
|
18172250 |
2008 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
TUSC2 restoration has been exploited as an anti-cancer therapy in various cancers in preclinical models, and clinically in patients with lung cancer.
|
28715648 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we evaluated the enhanced efficacy of cationic liposome-mediated delivery of FUS1 and human IL (hIL)-12 eukaryotic coexpression plasmid (pVITRO2-FUS1-hIL-12) against the human lung cancer in HuPBL-NOD/SCID mice model by local and systemic administration, and explored the related molecular mechanism.
|
24410728 |
2014 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This result demonstrates the potent tumor suppressive activity of the FUS1 gene and is a promising therapeutic agent for treatment of primary and disseminated human lung cancer.
|
15486560 |
2004 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
FUS1 mRNA transcripts could be detected on Northern blots in both normal lung and some lung cancer cell lines, but no endogenous FUS1 protein could be detected in a majority of lung cancer cell lines and small cell and non-small cell lung tumor tissues.
|
21645495 |
2011 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
TUSC2-erlotinib cooperativity in vitro could be reproduced in vivo in subcutaneous tumor growth and lung metastasis formation lung cancer xenograft mouse models.
|
26053020 |
2015 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because of the role of TUSC2 in regulating immune cells, we assessed TUSC2 efficacy on antitumor immune responses alone and in combination with anti-PD-1 in two <i>Kras</i>-mutant syngeneic mouse lung cancer models.
|
29339375 |
2018 |